1. Home
  2. BCDA vs MTEM Comparison

BCDA vs MTEM Comparison

Compare BCDA & MTEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • MTEM
  • Stock Information
  • Founded
  • BCDA N/A
  • MTEM N/A
  • Country
  • BCDA United States
  • MTEM United States
  • Employees
  • BCDA N/A
  • MTEM N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • MTEM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BCDA Health Care
  • MTEM Health Care
  • Exchange
  • BCDA Nasdaq
  • MTEM Nasdaq
  • Market Cap
  • BCDA 9.4M
  • MTEM 8.5M
  • IPO Year
  • BCDA N/A
  • MTEM N/A
  • Fundamental
  • Price
  • BCDA $2.78
  • MTEM $1.35
  • Analyst Decision
  • BCDA Strong Buy
  • MTEM
  • Analyst Count
  • BCDA 1
  • MTEM 0
  • Target Price
  • BCDA $60.00
  • MTEM N/A
  • AVG Volume (30 Days)
  • BCDA 82.6K
  • MTEM 24.2K
  • Earning Date
  • BCDA 08-07-2024
  • MTEM 08-08-2024
  • Dividend Yield
  • BCDA N/A
  • MTEM N/A
  • EPS Growth
  • BCDA N/A
  • MTEM N/A
  • EPS
  • BCDA N/A
  • MTEM N/A
  • Revenue
  • BCDA $468,000.00
  • MTEM $31,763,000.00
  • Revenue This Year
  • BCDA N/A
  • MTEM N/A
  • Revenue Next Year
  • BCDA $436.41
  • MTEM N/A
  • P/E Ratio
  • BCDA N/A
  • MTEM N/A
  • Revenue Growth
  • BCDA N/A
  • MTEM N/A
  • 52 Week Low
  • BCDA $2.62
  • MTEM $1.01
  • 52 Week High
  • BCDA $23.25
  • MTEM $9.45
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 34.41
  • MTEM 53.46
  • Support Level
  • BCDA $2.85
  • MTEM $1.21
  • Resistance Level
  • BCDA $3.66
  • MTEM $1.50
  • Average True Range (ATR)
  • BCDA 0.30
  • MTEM 0.11
  • MACD
  • BCDA 0.05
  • MTEM 0.02
  • Stochastic Oscillator
  • BCDA 8.33
  • MTEM 59.46

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About MTEM Molecular Templates Inc.

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.

Share on Social Networks: